Forest Once-Daily Namenda Positioned To Launch Ahead Of Immediate-Release Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest outlines top-line Phase III data showing benefit of a once-daily dose for treatment of dementia.
You may also be interested in...
Forest Looks To Licensing, Co-Promotion And Acquiring Products Going Forward To Boost Revenue
Upcoming patent expiration for the firm’s top drugs, combined with a modest pipeline, prompt the need to look outside.
Pfizer/Eisai’s Aricept Becomes First Treatment Approved For All Degrees of Alzheimer’s
Because Aricept is often used in combination with Namenda, though, Forest says it is not concerned about market share erosion.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.